Trial reportNature medicine2024
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
Registry-linked trialAbstract readClinical Trial, Phase IIAdaptive Clinical Trial
In one paragraph
Trial report in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07055399 (Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Chemotherapy-eclipse for Locally Advanced Cervical Cancer：A Single-arm, Open-label, Phase II Trial), which is not on this map. Cited by 48 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Chemotherapy-eclipse for Locally Advanced Cervical Cancer：A Single-arm, Open-label, Phase II Trial
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cancer-related fatigue during treatment with neoadjuvant and/or adjuvant immune checkpoint inhibitors: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Long-term outcomes in triple-negative breast cancer after a pathologic complete response: does the type of neoadjuvant therapy matter?Breast cancer research and treatment · 2026Pooled it
- Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial.Journal of gynecologic oncology · 2026Trial
- Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition in metastatic TNBC.Nature cancer · 2026Trial
- The immunology of human breast cancer.Nature reviews. Immunology · 2026Review
- Article
- Neoadjuvant therapy for stage II-III triple-negative breast cancer: Current evidence, clinical boundaries and emerging strategies (Review).Oncology letters · 2026Review
- Current and future therapies for triple-negative breast cancer.Journal of hematology & oncology · 2026Review
- Immune checkpoint inhibitor-associated uveitis in a patient with breast cancer and a remote history of Vogt-Koyanagi-Harada disease: a case report.International cancer conference journal · 2026Article
- Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.Current treatment options in oncology · 2026Review
- Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer.Current issues in molecular biology · 2026Review
- Review
- Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.Molecular cancer · 2026Review
- New Perspectives in the Management of Triple-Negative Breast Cancer.Breast care (Basel, Switzerland) · 2026Review
- Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer.NPJ breast cancer · 2026Article
- Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.NPJ breast cancer · 2026Article
- Review
- Murine models for triple-negative breast cancer with differential responsiveness to immunotherapy.bioRxiv : the preprint server for biology · 2026Article
- Review
- Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review.Current oncology (Toronto, Ont.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors.
Iris Nederlof *Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-7608-6515
Olga I Isaeva *Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-7377-0944
Manon de GraafDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Robbert C A M GielenDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Noor A M BakkerDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Adrianne L RolfesDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Hannah GarnerDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-6804-5040
Bram BoeckxLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.
Joleen J H TraetsDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ingrid A M MandjesBiometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Michiel de MaakerCore Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Thomas van BrusselLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.
Maksim ChelushkinDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-4284-9294
Elisa ChampanhetDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Marta Lopez-YurdaBiometrics Department, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-3678-3222
Koen van de VijverDepartment of Pathology, UZ Gent - Universitair Ziekenhuis Gent, Gent, Belgium.ORCID http://orcid.org/0000-0002-2026-9790
José G van den BergDepartment of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ingrid HoflandCore Facility Molecular Pathology & Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Natasja KliouevaDepartment of Pathology, OLVG Hospital, Amsterdam, the Netherlands.
Ritse M MannDepartment of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Claudette E LooDepartment of Radiology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Frederieke H van DuijnhovenDepartment of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Victoria SkinnerDepartment of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Sylvia LuykxMedical Oncology Department, Tergooi Hospital - locatie Hilversum, Hilversum, the Netherlands.
Emile KerverDepartment of Oncology, OLVG Hospital, Amsterdam, the Netherlands.
Ekaterina KalashnikovaNatera, San Carlos, CA, USA.
Marloes G J van DongenDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Gabe S SonkeDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-8088-9628
Sabine C LinnDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-5541-0347
Christian U BlankDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-7945-5846
Karin E de VisserDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-0293-868X
Roberto SalgadoDepartment of Pathology, ZAS hospitals, Antwerp, Belgium.ORCID http://orcid.org/0000-0002-1110-3801
Lodewyk F A WesselsOncode Institute, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0002-1656-6995
Caroline A DrukkerDepartment of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ton N SchumacherOncode Institute, Utrecht, the Netherlands.ORCID http://orcid.org/0000-0003-0517-8804
Hugo M HorlingsDepartment of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-4782-8828
Diether LambrechtsLaboratory for Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.ORCID http://orcid.org/0000-0002-3429-302X
Marleen KokDivision of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. m.kok@nki.nl.ORCID http://orcid.org/0000-0001-9043-9815
Funding
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) 09150172010043
Abstract
Immune checkpoint inhibition (ICI) with chemotherapy is now the standard of care for stage II-III triple-negative breast cancer; however, it is largely unknown for which patients ICI without chemotherapy could be an option and what the benefit of combination ICI could be. The adaptive BELLINI trial explored whether short combination ICI induces immune activation (primary end point, twofold increase in CD8
Indexed as
CD8-Positive T-LymphocytesIpilimumabLymphocytes, Tumor-InfiltratingNeoadjuvant TherapyNivolumabTriple Negative Breast NeoplasmsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCTLA-4 AntigenFemaleHumansImmune Checkpoint InhibitorsMiddle AgedNeoplasm StagingProgrammed Cell Death 1 ReceptorCTLA-4 AntigenImmune Checkpoint InhibitorsIpilimumabNivolumabProgrammed Cell Death 1 Receptor
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT07055399ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.